Status:
UNKNOWN
Allogeneic Adoptive Immune Therapy for Advanced AIDS Patients
Lead Sponsor:
Beijing 302 Hospital
Collaborating Sponsors:
The 6th people's Hospital of Xinjiang province
The 4th people's hospital of Nanning City
Conditions:
AIDS Patients
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Combined antiretroviral therapy (ART) efficiently suppresses viral replication and markedly decreases mortality among patients with HIV-1 infection/AIDS. While the advanced AIDS patients with CD4+T ce...
Detailed Description
Combined antiretroviral therapy (ART) efficiently suppress viral replication and dramatically decrease mortality of the disease in HIV-1/AIDS patients.1 While in cART naive patients with chronic human...
Eligibility Criteria
Inclusion
- Male or female, aged at 18 years (including) -65 years old
- Advanced AIDS patients with AIDS-related events
- Advanced patients with CD4 count less than or equal to 200 cells/uL, including end-stage patients with CD4 count less than or equal to 50 cells/uL before entry and at screening
- Sign informed consent, do not participate in other clinical trails during the period
Exclusion
- Pregnancy, lactation and those who are not pregnant but do not take effective contraceptives measures
- Combined with other serious organic diseases while didn't related with AIDS
- HIV-2 infection
- Allergic to blood products
- Under long term immunosuppressive therapy
- Combined with malignant tumors
- Drug addicts within half-one year before the test
- Poor compliance to antiviral therapy; take part in other clinical trials at present
Key Trial Info
Start Date :
October 11 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT04098770
Start Date
October 11 2019
End Date
December 30 2024
Last Update
January 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing 302 Hospital of China
Beijing, Beijing Municipality, China, 100039